Search

Displaying results 4301 - 4310 of 8700 in total
  1. Drug

    Pralidoxime

    go.drugbank.com/drugs/DB00733
    ApprovedInvestigationalVet approved

    Pralidoxime is an antidote to organophosphate pesticides and chemicals.

  2. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid.

  3. Drug

    Fleroxacin

    go.drugbank.com/drugs/DB04576
    Experimental

    Fleroxacin is not an inhibitor of CYP1A2.[A39048]

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  5. Drug

    LC16M8

    go.drugbank.com/drugs/DB05019
    Investigational

    It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection.

  6. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules. … CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

  7. Drug

    Fluspirilene

    go.drugbank.com/drugs/DB04842
    ApprovedWithdrawn

    A long-acting injectable antipsychotic agent used for chronic schizophrenia.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Glycylglutamine

    go.drugbank.com/drugs/DB15990
    Investigational

    Mixtures: GLAMIN SOLUTION FOR INFUSION, Trimix MOF Emulsion zur Infusion
  9. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    It was approved by the FDA for use in combination with a reduced-calorie diet in 1999.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  10. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is designed for intravenous administration for acute use … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.

    Categories: Experimental Unapproved Treatments for COVID-19